@article {Li509, author = {Wenhao Li and William Alazawi}, title = {Non-alcoholic fatty liver disease}, volume = {20}, number = {5}, pages = {509--512}, year = {2020}, doi = {10.7861/clinmed.2020-0696}, publisher = {Royal College of Physicians}, abstract = {Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD is defined by excess fat in the liver and has a multidirectional relationship with metabolic syndrome. The prevalence of NAFLD has risen rapidly in recent years in line with the obesity epidemic and associated increases in type 2 diabetes, hypertension and hypercholesterolaemia. Patients with NAFLD are at risk of cardiovascular disease and cancer, and in a proportion of individuals, NAFLD is associated with liver damage. This article summarises the epidemiology of NAFLD, the clinical approach to risk-assessing patients and briefly outlines current and future management options.}, issn = {1470-2118}, URL = {https://www.rcpjournals.org/content/20/5/509}, eprint = {https://www.rcpjournals.org/content/20/5/509.full.pdf}, journal = {Clinical Medicine} }